Фармакоэкономика (Mar 2015)
PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS
Abstract
Pharmacoeconomic study of treatment primary open-angle glaucoma with carbonic anhydrise inhibitors by mean of costefficacy and budget impact analysis. Results have shown, that Azopt has benefits compare with Dorzopt and Trusopt from cost-efficacy perspective and can be claimed dominant. Futhermore Azopt in comparison with Trusopt provides cost-saving and advantage in terms of budget impact analysis.